Joseph R. Berger, MD

home / authors / joseph-r-berger-md

Professor of neurology, and associate chief, Multiple Sclerosis Division, Hospital of the University of Pennsylvania

Articles

AUPN Leading Edge Episode 4: How Much Is a Neurologist Worth? Factoring the Downstream

October 13th 2022

AUPN Leading Edge Episode 4 features Rohit Das, MD, and Joseph R. Berger, MD, who discuss how neurologists are undervalued in academic and non-academic settings when their compensation is predicated on RVUs alone. [LISTEN TIME: 26 minutes]

AUPN Leadership Minute Episode 24: How Much Is a Neurologist Worth: Factoring the Downstream

Alissa Willis, MD;Joseph R. Berger, MD

August 1st 2022

Episode 24 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Joseph R. Berger, MD, of the University of Pennsylvania. [WATCH TIME: 7 minutes]

Advice for Managing MS

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

May 13th 2021

Joseph R. Berger, MD, and Fred D. Lublin, MD, offer advice to community physicians and neurologists in managing patients with multiple sclerosis.

Future of MS Management

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

May 6th 2021

Kristen Krysko, MD, and Robert Fox, MD, look to the future of multiple sclerosis management.

Exercise and MS Fatigue

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

May 6th 2021

Considerations regarding the role of exercise and combatting fatigue when treating patients with multiple sclerosis.

MS: Nutrition and Managing Cognitive Impairment

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

April 29th 2021

The importance of proper nutrition as a therapy for symptom control in multiple sclerosis and some strategies to manage cognitive impairment.

Shared Decision-Making and Complementary Therapies in Progressive MS

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

April 29th 2021

Joseph R. Berger, MD, elaborates on the importance of shared decision making in the treatment of multiple sclerosis and how it relates to complementary and natural therapies for symptom control.

Age Considerations: Patients With Nonactive MS Progression

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

April 22nd 2021

Considerations regarding age in treatment decisions in patients with nonactive multiple sclerosis progression.

Monitoring Response in Progressive MS

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

April 22nd 2021

Experts discuss how they monitor response to multiple sclerosis therapies and disease progression.

Ibudilast for Progressive Treatment

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

April 15th 2021

Experts in progressive multiple sclerosis summarize the phase 2 SPRINT-MS trial and the rationale for treating patients with ibudilast.

Nonactive MS: Treatment Therapies

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

April 15th 2021

A discussion of how experts treat nonactive multiple sclerosis in terms of trial results or symptom management and how decisions are based on patient age.

Patient Selection in MS Treatment

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

April 8th 2021

Experts in the field of multiple sclerosis discuss patient selection for drugs based on disease activity.

Progressive MS Treatment: Ocrelizumab

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

April 8th 2021

Kristen Krysko, MD, summarizes the results of the phase III ORATORIO trial and discusses the rationale for using ocrelizumab for the treatment of progressive multiple sclerosis.

MS Treatment: EXPAND Study Versus ASCEND Study

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

April 1st 2021

Experts in the field of multiple sclerosis compare the results of the EXPAND study to the results of the ASCEND study.

Siponimod for SPMS Treatment

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

April 1st 2021

Robert Fox, MD, discusses the rationale for using siponimod for the treatment of progressive multiple sclerosis as well as the practical implications of the phase 3 EXPAND trial.

Treating PPMS Versus SPMS

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

March 25th 2021

A comparison of various factors considered when treating primary progressive multiple sclerosis versus secondary progressive multiple sclerosis.

Classification and Diagnosis of SPMS

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

March 24th 2021

Fred D. Lublin, MD, leads a discussion about the different classifications of secondary progressive multiple sclerosis, including the relationship between disease activity and progression of disease.